Published in Oncoimmunology on April 02, 2015
Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther (2017) 0.76
A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model. Mol Ther Oncolytics (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
T cell receptor antagonist peptides induce positive selection. Cell (1994) 18.66
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 9.42
Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity (2009) 9.28
The microenvironment of the tumour-host interface. Nature (2001) 9.17
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest (2007) 5.05
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature (2011) 4.61
Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med (2013) 3.92
Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A (2006) 3.70
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 2.81
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol (2005) 2.74
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
Going viral with cancer immunotherapy. Nat Rev Cancer (2014) 2.27
The plasticity and stability of regulatory T cells. Nat Rev Immunol (2013) 2.15
Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med (2007) 2.15
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res (2008) 2.15
Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol (2012) 2.04
An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity (2013) 1.98
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res (2014) 1.73
Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg (2006) 1.73
Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol (2010) 1.70
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 1.60
IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res (2012) 1.55
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med (2012) 1.52
Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev (2009) 1.38
Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther (2008) 1.34
Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res (2008) 1.30
Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology (2013) 1.29
Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22
Targeting cancer-initiating cells with oncolytic viruses. Mol Ther (2009) 1.18
Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res (2002) 1.14
Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol (2010) 1.10
DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol (2009) 1.09
Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer (2009) 1.08
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol (2008) 1.02
Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. J Clin Invest (2011) 1.01
Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. J Immunol (2012) 0.98
Glioma virus therapies between bench and bedside. Neuro Oncol (2014) 0.95
Oncolytic adenoviral therapy for glioblastoma multiforme. Neurosurg Focus (2006) 0.90
Rewiring cancer cell death to enhance oncolytic viro-immunotherapy. Oncoimmunology (2013) 0.90
Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication. Cancer Res (2005) 0.89
N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy. Mol Ther (2013) 0.85
An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy. Int J Oncol (2007) 0.84
The role of regulatory T-cells in glioma immunology. Clin Neurol Neurosurg (2014) 0.83
Oncolytic viruses targeting tumor stem cells. Cancer Res (2014) 0.81
Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy. Oncoimmunology (2013) 0.81
Tumor hypoxia: Impact on gene amplification in glioblastoma. Int J Oncol (2008) 0.79